February 2019 reports are now online. These documents are available to our stakeholders only (username and password required). Access is via the 'Financial Headlines' link in the Prescribing Analysis Reports section of this site.
Published: Wed, 17 Apr 2019 08:09:29 +0000
Our April 2019 Monthly Horizon Scanning Report is now available.
Please see our Monthly Horizon Scanning Reports page.
Published: Fri, 12 Apr 2019 12:45:42 +0000
The updated medicines in practice document reviewing the cardiovascular outcomes associated with SGLT2 inhibitors is now online. This publication is specifically designed to support stakeholder Medicines Management services to maximise health gains through the optimum use of medicines by influencing and changing prescribing behaviour.
Published: Mon, 08 Apr 2019 13:42:02 +0000
Updates to our cardiovascular, dementia, diabetes and respiratory reports with 2018/2019 Q3 data are now available online. These are available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the 'Therapeutic' menu item followed by the relevant BNF heading)
Published: Wed, 03 Apr 2019 11:02:29 +0000
April 2018 to Dec 2018 Growth Contrast Tool now online. These documents are available to our stakeholders only (username and password required). Access is via the 'Growth Contrast Tool' link in the Prescribing Analysis Reports section of this site.
Published: Wed, 27 Mar 2019 14:35:03 +0000
Published: Thu, 21 Mar 2019 15:18:21 +0000
January 2019 reports are now online. These documents are available to our stakeholders only (username and password required). Access is via the 'Financial Headlines' link in the Prescribing Analysis Reports section of this site.
Published: Thu, 21 Mar 2019 12:29:49 +0000
Published: Mon, 18 Mar 2019 12:10:23 +0000
Our March 2019 Monthly Horizon Scanning Report is now available.
Please see our Monthly Horizon Scanning Reports page.
Published: Fri, 08 Mar 2019 10:46:20 +0000
The new evaluation report on the use doxylamine and pyridoxine (Xonvea®) for the treatment of nausea and vomiting of pregnancy is now online. This review aims to give objective information and guidance on efficacy, adverse effects, place in treatment and arrangements for prescribing to commissioners of health services, prescribers and others.
Published: Thu, 28 Feb 2019 17:43:32 +0000
NICE have published a summary of guidance and safety advice on use of valproate in children, young people and adults – including updated recommendations on prescribing for women or girls with childbearing potential: Do not prescribe valproate for any condition, unless there is no other effective or tolerated treatment available, and only if the terms of the pregnancy Continue Reading »Memos and Alerts Prescribing Newsletter
Published: Tue, 09 Apr 2019 11:11:27 +0000
NHS England have published advice and information on the recommended vaccines for the 2019/20 seasonal flu vaccination programme – to supplement the National flu immunisation programme plan for 2019/20.2018/19 and 2019/20 Flu Campaigns
Published: Tue, 09 Apr 2019 10:55:30 +0000
The RCGP TARGET [Treat Antibiotics Responsibly, Guidance, Education & Tools ] Antibiotic Toolkit has been refreshed and updated in recent months. The updated toolkit now includes a comprehensive guide to the available resources with advice and tips on using them in practice. Among the refreshed resources are: new versions of the Treating Your Infection – Respiratory Tract Infection Continue Reading »
The post TARGET Antibiotic Toolkit – Refreshed Patient Leaflets appeared first on NECS Medicines Optimisation.Antibiotics News Prescribing Newsletter antibiotic antibiotic stewardship common infection minor infection patient leaflets respiratory tract infection rti self-care target urinary tract infection UTI
Published: Mon, 08 Apr 2019 12:14:12 +0000
The Neonatal and Paediatric Pharmacists’ Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) have issued a joint statement on using standardised strengths of unlicensed liquid medicines in children. The two bodies strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH- and NPPG- recommended strength, where one exists. There are currently 17 Continue Reading »
The post Unlicensed Medicines for Children – Use Standard Strengths appeared first on NECS Medicines Optimisation.News Prescribing Newsletter
Published: Wed, 27 Mar 2019 19:24:42 +0000
NICE have updated and revised several Key Therapeutic Topic (KTT) documents and added two new topics to the KTT collection of evidence summaries to support medicines optimisation: KTT5 Asthma: medicines safety priorities UPDATE KTT6 Hypnotics UPDATE KTT7 Antipsychotics in people living with dementia UPDATE KTT9 Antimicrobial stewardship- prescribing antibiotics UPDATE KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Continue Reading »News Prescribing Newsletter
Published: Wed, 27 Mar 2019 19:16:36 +0000
We have recently received 2 reports of fatal adverse reactions to the yellow fever vaccine (Stamaril).
Ongoing patient survey data suggest that more effort is needed by clinicians to achieve full and timely compliance with the valproate Pregnancy Prevention Programme and meet the goal to rapidly reduce and eventually eliminate the harms of valproate in pregnancy in view of its serious teratogenicity. We have updated the Annual Risk Acknowledgement Form, which should be used during annual specialist review of all women and girls of childbearing potential on valproate medicines (irrespective of indication).
Clinical trials, including interim findings from a randomised trial, show an increased risk of depression, suicidal ideation or behaviour, or self-injury in patients with systemic lupus erythematosus receiving belimumab compared with those receiving placebo in addition to standard therapy.
As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3.
Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya▼, Stribild) is lower during the second and third trimesters of pregnancy than postpartum.
Letters were sent about Xeljanz▼ (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya▼, Stribild▼, Tybost, and belimumab (Benlysta▼).
Alerts were issued about Pagewriter Cardiographs and Efficia Monitors and Fresenius 5008 & 5008S haemodialysis machines.
Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics.
Onivyde has been associated with reports of serious thromboembolic events, such as pulmonary embolism, venous thrombosis, and arterial thromboembolism.
New guidance on contraceptive methods and frequency of pregnancy testing to reduce inadvertent exposures during pregnancy in a woman taking a medicine of teratogenic potential.
Northern Treatment Advisory Group: http://ntag.nhs.uk/html/latest_news.html